<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="324">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01012895</url>
  </required_header>
  <id_info>
    <org_study_id>AI447-011</org_study_id>
    <secondary_id>2010-024637-23</secondary_id>
    <nct_id>NCT01012895</nct_id>
  </id_info>
  <brief_title>Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care</brief_title>
  <official_title>Parallel, Open-Label, Randomized, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-790052 and BMS-650032 in Combination in Null Responders to Standard of Care Infected With Chronic Hepatitis C Virus Genotype 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <authority>European Union: European Medicines Agency</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether BMS-650032 and BMS-790052 in combination
      alone, together with Ribavirin, or together with Interferon and Ribavirin are effective in
      the treatment of Hepatitis C in patients who have not responded to prior therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Hepatitis C virus (HCV) ribonucleic acid (RNA) levels in subjects' blood before, during and after treatment</measure>
    <time_frame>12 weeks post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessments will be based on medical review of the frequency of SAEs and AEs, discontinuations due to AEs, and abnormalities observed from vital sign and ECG measurements, physical examinations and clinical laboratory results</measure>
    <time_frame>12 weeks post-treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Serious Adverse Events (SAEs), Adverse Events (AEs), Electrocardiogram (ECG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter maximum observed concentration [Cmax] will be derived from plasma concentration versus time. Trough concentration (Ctrough) and sparse Pharmacokinetics (PK) samples will also be collected.</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter trough observed concentration [Cmin] will be derived from plasma concentration versus time. Trough concentration (Ctrough) and sparse Pharmacokinetics (PK) samples will also be collected.</measure>
    <time_frame>Days 1, Days 7, Days 14, Weeks 4, Weeks 8, Weeks 12, Weeks 16</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter time of maximum observed concentration [Tmax] will be derived from plasma concentration versus time. Trough concentration (Ctrough) and sparse Pharmacokinetics (PK) samples will also be collected.</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter area under the concentration-time curve in one dosing interval [AUC(TAU)] will be derived from plasma concentration versus time. Trough concentration (Ctrough) and sparse Pharmacokinetics (PK) samples will also be collected.</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Arm 1: Sentinel A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-790052 (60mg) once daily + BMS-650032 (600 mg) twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Sentinel B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-790052 (60mg) once daily + BMS-650032 (600mg) twice daily + Pegylated-interferon alfa-2a + Ribavirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Expansion A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-790052 (60mg) once daily + BMS-650032 (200mg) twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: Expansion A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-790052 (60mg) once daily + BMS-650032 (200mg) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5: Expansion B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-790052 (60mg) once daily + BMS-650032 (200 mg) twice daily + Pegylated-interferon alfa-2a + Ribavirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6: Expansion B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-790052 (60mg) once daily + BMS-650032 (200 mg) once daily + Pegylated-interferon alfa-2a + Ribavirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7: Expansion B3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-790052 (60 mg) once daily + BMS-650032 (200 mg) twice daily + Ribavirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-790052</intervention_name>
    <description>Tablets, Oral, 60 mg, once daily, 24 weeks</description>
    <arm_group_label>Arm 1: Sentinel A</arm_group_label>
    <arm_group_label>Arm 2: Sentinel B</arm_group_label>
    <arm_group_label>Arm 3: Expansion A1</arm_group_label>
    <arm_group_label>Arm 4: Expansion A2</arm_group_label>
    <arm_group_label>Arm 5: Expansion B1</arm_group_label>
    <arm_group_label>Arm 6: Expansion B2</arm_group_label>
    <arm_group_label>Arm 7: Expansion B3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-650032</intervention_name>
    <description>Tablets, Oral, 600 mg, twice daily, 24 weeks</description>
    <arm_group_label>Arm 1: Sentinel A</arm_group_label>
    <arm_group_label>Arm 2: Sentinel B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-650032</intervention_name>
    <description>Tablets, Oral, 200mg, twice daily, 24 weeks</description>
    <arm_group_label>Arm 3: Expansion A1</arm_group_label>
    <arm_group_label>Arm 5: Expansion B1</arm_group_label>
    <arm_group_label>Arm 7: Expansion B3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-650032</intervention_name>
    <description>Tablets, Oral, 200 mg, once daily, 24 weeks</description>
    <arm_group_label>Arm 4: Expansion A2</arm_group_label>
    <arm_group_label>Arm 6: Expansion B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated-interferon alfa-2a</intervention_name>
    <description>Syringe, Subcutaneous Injection, 180 µg, once weekly</description>
    <arm_group_label>Arm 2: Sentinel B</arm_group_label>
    <arm_group_label>Arm 5: Expansion B1</arm_group_label>
    <arm_group_label>Arm 6: Expansion B2</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Tablets, Oral
For subjects weighing &lt; 75 kg: 1000 mg; For subjects weighing ≥ 75 kg: 1200 mg
Twice daily (&lt; 75 kg: 400 mg in ante meridian (AM) and 600 mg in post meridian (PM); ≥ 75 kg: 600 mg in AM and PM), 24 weeks</description>
    <arm_group_label>Arm 2: Sentinel B</arm_group_label>
    <arm_group_label>Arm 5: Expansion B1</arm_group_label>
    <arm_group_label>Arm 6: Expansion B2</arm_group_label>
    <arm_group_label>Arm 7: Expansion B3</arm_group_label>
    <other_name>Copegus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects ages 18 to 70 years

          -  HCV-Infected Genotype 1 Null responders to current standard of care

          -  Expansion Cohorts A1 and A2 are restricted to patients infected with HCV Genotype 1b
             only.

        Exclusion Criteria:

          -  Evidence of a medical condition associate with chronic liver disease other than HCV

          -  History of variceal bleeding, hepatic encephalopathy, or ascites requiring management
             with diuretics or paracentesis

          -  History of Cancer within 5 years of enrollment

          -  History of gastrointestinal disease or surgical procedure (except Cholecystectomy)

          -  History of clinically significant cardiac disease

          -  History of Glucose-6-phosphate dehydrogenase (G6PD) deficiency

          -  Documented cirrhosis within 12 months prior to dosing

          -  Positive for Human Immunodeficiency Virus (HIV) or Hepatitis B Virus (HBV)

          -  Pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Liver Centers</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Jose Gastroenterology</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Colorado Denver &amp; Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Center For Liver Disease</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Clinical Research Institute, Llc</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Medical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Research</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Clichy Cedex</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Creteil Cedex</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Marseille Cedex 08</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 23, 2015</lastchanged_date>
  <firstreceived_date>November 12, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
